Third Harmonic Bio — Investor Presentation (July 2023)
17 slides from Third Harmonic Bio's investor presentation, Jul 25, 2023
Slide 1: Focused on advancing the next wave of medicine for inflammatory diseases
FOCUSED On advancing the next wave of medicine for inflammatory diseases JULY 2023 ©2023 THIRD HARMONIC BIO Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. Any statements made in this presentation that are not statements of historical fact, inclu
Slide 3: Focused on KIT Inhibition to Treat Mast Cell-Mediated Inflammatory Diseases
“PIPELINE-IN-A-TARGET” POTENTIAL SELECTIVE ORAL KIT INHIBITORS KIT: A NOVEL, CLINICALLY VALIDATED TARGET LARGE ESTABLISHED MARKETS WITH HIGH UNMET NEED Third Harmonic Bio: Focused on KIT Inhibition to Treat Mast Cell-Mediated Inflammatory Diseases Millions of patients living with severe mast cell-me
Slide 4: Mast Cells are a Fulcrum of Inflammation
MAST CELL Receptor-binding agonists IgE Complement Neuropeptides Microbial products Cytokines TSLP Chemokines Physical activators Temperature Pressure Cell-cell contact Pre-formed mediators Histamine IL-4, IL-13 TNF, GM-CSF Proteases Serotonin Heparin Newly synthesized mediators Prostaglandins Leuko
Slide 5: KIT is the Master Regulator of Mast Cell Function and Survival
KIT is the Master Regulator of Mast Cell Function and Survival Intracellular small molecule approach to KIT inhibition offers multiple potential therapeutic advantages KIT Master regulator of mast cell proliferation, migration, activation and survival KIT inhibition drives both mast cell inactivatio
Slide 6: THB001 Clinical results from first generation oral KIT inhibitor
THB001 Clinical results from first generation oral KIT inhibitor
Slide 7: First-Generation Product Candidate: THB001
First-Generation Product Candidate: THB001 Early results support the potential of oral KIT inhibition and inform next-gen development THB001 demonstrated high potency and selectivity for KIT à mast cell depletion and disease model efficacy in multiple nonclinical studies Phase 1a 14-day healthy volu
Slide 8: THB001 Discontinued Phase 1b Chronic Inducible Urticaria Study Overview
THB001 Discontinued Phase 1b Chronic Inducible Urticaria1 Study Overview Dose escalation study designed to interrogate potential for therapeutic index optimization Design and Objectives 3 doses (1:1:1) of THB001 (total N=30) for 12 weeks Pharmacokinetics and serum tryptase levels Mean reduction in c
Slide 9: THB001 in Phase 1b CINDU Study Safety Summary
11 1000 THB001 in Phase 1b CINDU Study Safety Summary No serious or severe adverse events (AEs) Two moderate AEs of transaminitis which resolved at weeks 17 and 25 of follow-up All other AEs were mild Overall profile consistent with on-target effects of KIT inhibition observed in the Phase 1a study
Slide 10: THB001 Generated Responses at Lowest Planned Dose in Phase 1b Study
THB001 Generated Responses at Lowest Planned Dose in Phase 1b Study 4 of 5 subjects reached partial (n=2) or complete (n=2) Critical Temperature Threshold responses Rapid tryptase reduction: -83% mean change from baseline by week 1 largely consistent with Phase 1a results Strong correlation between
Slide 11: Understanding Hepatic Effects of THB001
Understanding Hepatic Effects of THB001 Generating mechanistic understanding allows for differentiation of next-generation candidate Conducting studies characterizing liver metabolism and phenotypic effects of THB001 Employing a comprehensive approach: Assessing evidence for off-target biology liabi
Slide 12: THB001 Shows Evidence for Formation of a Toxic Reactive Metabolite
THB001 Shows Evidence for Formation of a Toxic Reactive Metabolite Three findings from mechanistic studies provide potential basis for observed transaminitis Studies identify major metabolite in human plasma which is formed via a reactive intermediate Metabolite present at higher levels in human pla
Slide 13: THB335 Next generation oral KIT inhibitor
THB335 Next generation oral KIT inhibitor
Slide 14: THB335 Potent and Selective Small Molecule KIT Inhibitor
THB335 Potent and Selective Small Molecule KIT Inhibitor Maintained Kinase Inhibition Profile to THB001 but Lacking Evidence for Reactive Metabolite Formation THB001 THB335 KIT IC50 23 nM 9.5 nM PDGFRa Selectivity >100-fold >100-fold CSF1R Selectivity 65-fold >100-fold Off-target cell viability No e
Slide 15: THB335 Demonstrates Favorable Nonclinical Profile
Potent mast cell depletion across relevant tissue types Favorable nonclinical pharmacokinetic profile, including high oral bioavailability, metabolic stability and long circulating half-life Improved solubility and lipophilicity compared to THB001 No liver toxicity signal observed at high multiples
Slide 16: Third Harmonic Bio Next Steps
Third Harmonic Bio Next Steps Advancing THB355 back toward the clinic with a longer-term view toward franchise expansion THB335 U.S. IND filing and clinical trial initiation anticipated in 1H 2024 Targeting chronic spontaneous urticaria as initial clinical indication Planned expansion into additiona
Slide 17: Advancing the next wave of medicine for inflammatory diseases
ADVANCING the next wave of medicine for inflammatory diseases
Third Harmonic Bio — Investor Presentation (July 2023) on 6ix